AFP and hCGβ as Prognostic Markers in NET Patients
Author Information
Author(s): Shah T, Srirajaskanthan R, Bhogal M, Toubanakis C, Meyer T, Noonan A, Witney-Smith C, Amin T, Bhogal P, Sivathasan N, Warner B, Hochhauser D, Caplin M E
Primary Institution: Neuroendocrine Tumour Unit, Centre for Gastroenterology, Royal Free Hospital, London, UK
Hypothesis
What is the diagnostic and prognostic value of serum α-fetoprotein (AFP) and human chorionic gonadotrophin-β (hCGβ) in neuroendocrine tumours (NETs)?
Conclusion
AFP and hCGβ are clinically important in NETs and when elevated are poor prognostic markers.
Supporting Evidence
- 9.5% of patients had elevated AFP levels.
- 12.3% of patients had elevated hCGβ levels.
- Patients with elevated AFP and hCGβ had poorer survival outcomes.
- Rising AFP levels correlated with worse survival.
- Rising hCGβ levels also correlated with worse survival.
Takeaway
This study found that two blood tests, AFP and hCGβ, can help doctors understand how serious neuroendocrine tumors are and predict how well patients might do.
Methodology
A database of 360 NET patients was created, and statistical analyses were performed to assess the relationship between AFP, hCGβ, and other tumor markers.
Limitations
The study is retrospective and may not account for all variables affecting patient outcomes.
Participant Demographics
Patients included both genders with a mean age of around 55 years.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website